FDA Approves Radiohybrid PET Diagnostic Agent Posluma for PSMA-Positive Lesions in Prostate CancerMay 30th 2023
The PET diagnostic imaging agent, flotufolastat F 18 injection has been approved by the FDA for the identification of prostate-specific membrane antigen–positive lesions in men with prostate cancer
Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income CountriesMay 25th 2023
Pediatric patients with leukemia in low- and middle-income countries saw improvements in survival outcomes following implementation of the WHO Framework for Action model.
Minimally Invasive Distal Pancreatectomy Proves Noninferior to Open Distal Pancreatectomy in Resectable Pancreatic CancerMay 25th 2023
Minimally invasive distal pancreatectomy was a safe and effective alternative compared with open distal pancreatectomy in patients with resectable pancreatic cancer.
Pembrolizumab Plus Lenvatinib Gains NICE Recommendation for Previously Treated Advanced or Recurrent Endometrial CancerMay 24th 2023
The United Kingdom’s National Institute for Health and Care Excellence has updated their guidelines to recommend pembrolizumab plus lenvatinib for patients with previously treated endometrial cancer.
Epcoritamab Obtains Accelerated Approval for Relapsed/Refractory DLBCLMay 19th 2023
The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.
Addition of Cabozantinib to Nivolumab/Ipilimumab Boosts PFS, But also AEs, in Advanced RCCMay 19th 2023
Cabozantinib, in combination with nivolumab and ipilimumab, improved progression-free survival in patients with advanced renal cell carcinoma, but the rate of grade 3/4 adverse events was 79%.
Nurses Highlight How to Help Patients Receiving Radiation Therapy Cope with Financial and Workplace StressorsMay 18th 2023
Hilda Haynes-Lewis, PhD, ANP-BC, AOCNP, and Rosaleen Bloom, PhD, APRN, ACNS-BC, AOCNS, discuss the financial stressors that face patients undergoing radiation.
Preoperative Treatment with Atezolizumab/Epirubicin Plus Trastuzumab/Pertuzumab Elicits High pCR Rate in Patients With Early HER2+ Positive Breast CancerMay 17th 2023
Patients with early-stage HER2-positive breast cancer experienced a high rate of pathologic complete response with combined preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab.